Tag: trastuzumabHerceptin

Articles

• Foods to eat and avoid during treatment with Herceptin
• Foods to eat and avoid for HER2+ patients and survivors
• HER2 positive breast cancer prognosis

News

08/06/24

Apple flavonoid phloretin enhances anti-cancer effects of Herceptin

10/07/20

Differences in HER2 expression between tumors affects outcomes

09/10/19

Watercress compound PEITC inhibits progression of HER2+ BC

05/01/16

Six-month delay in starting Herceptin linked to reduced survival

07/22/12

Inflammation can contribute to resistance to Herceptin

12/01/11

Herceptin + anthracycline chemo increases risk of cardiomyopathy

Studies

• Antitumor properties of bromelain loaded trastuzumab conjugated niosomes in HER2+ breast cancer cells Cite
  Tut E, Guldu OK, Medine EI. Antitumor properties of bromelain loaded trastuzumab conjugated niosomes in HER2+ breast cancer cells. Journal of Drug Delivery Science and Technology. Elsevier BV; 2024; 101:106243 10.1016/j.jddst.2024.106243
• Apple polyphenol phloretin inhibits type II glucose transporter and enhances anti-HER2 antibody drug binding as an adjuvant treatment for HER2-positive breast cancer Cite
  Chang H, Cheng T, Tu S, Liao P, Lee Y, Ho C, et al. Apple polyphenol phloretin inhibits type II glucose transporter and enhances anti-HER2 antibody drug binding as an adjuvant treatment for HER2-positive breast cancer. Food Science and Human Wellness. Tsinghua University Press; 2024; 10.26599/fshw.2024.9250251
• Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial Cite
  Kettana KM, El‑Haggar SM, Alm El-Din MA, El‑Afify DR. Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial. Medical Oncology. Springer Science and Business Media LLC; 2024; 41 10.1007/s12032-024-02426-1
• Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression Cite
  Franceschi BT, Bezerra PHA, Torqueti MR. Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-024-01590-6
• Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Cite
  Masuda Y, Yamashita S, Nakayama Y, Shimizu R, Konishi M. Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. Biological and Pharmaceutical Bulletin. Pharmaceutical Society of Japan; 2024; 47:840-847 10.1248/bpb.b23-00802
• Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab Cite
  Zhou S, Cirne F, Chow J, Zereshkian A, Bordeleau L, Dhesy-Thind S, et al. Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab. The Oncologist. Oxford University Press (OUP); 2023; 28:e712-e722 10.1093/oncolo/oyad086
• Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan Cite
  Haque R, Chen LH, Oestreicher N, Lalla D, Chlebowski RT. Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan. Breast Cancer: Targets and Therapy. Informa UK Limited; 2023; Volume 15:637-645 10.2147/bctt.s420061
• Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study Cite
  Taylor C, McGale P, Probert J, Broggio J, Charman J, Darby SC, et al. Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study. BMJ. BMJ; 2023;:e074684 10.1136/bmj-2022-074684
• A comprehensive review of the health benefits of flaxseed oil in relation to its chemical composition and comparison with other omega-3-rich oils Cite
  Al-Madhagy S, Ashmawy NS, Mamdouh A, Eldahshan OA, Farag MA. A comprehensive review of the health benefits of flaxseed oil in relation to its chemical composition and comparison with other omega-3-rich oils. European Journal of Medical Research. Springer Science and Business Media LLC; 2023; 28 10.1186/s40001-023-01203-6
• Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study Cite
  Shi Y, Qiu Z, Yu J, Li Z, Hua S, Chen Y, et al. Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11102-y
• Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy Cite
  Arinno A, Maneechote C, Khuanjing T, Prathumsap N, Chunchai T, Arunsak B, et al. Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. Elsevier BV; 2023; 1869:166618 10.1016/j.bbadis.2022.166618
• Estimating the incidence of breast cancer recurrence using administrative data Cite
  Habbous S, Barisic A, Homenauth E, Kandasamy S, Forster K, Eisen A, et al. Estimating the incidence of breast cancer recurrence using administrative data. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06812-z
• Long-Term Survival Outcomes of Patients with Small (≤1 cm) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study Cite
  Liikanen JS, Leidenius M, Joensuu H, Meretoja TJ. Long-Term Survival Outcomes of Patients with Small (≤1 cm) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study. Breast Care. S. Karger AG; 2022; 17:279-287 10.1159/000520793
• Protective Effect of Curcumin, Chrysin and Thymoquinone Injection on Trastuzumab-Induced Cardiotoxicity via Mitochondrial Protection Cite
  Shirmard LR, Shabani M, Moghadam AA, Zamani N, Ghanbari H, Salimi A. Protective Effect of Curcumin, Chrysin and Thymoquinone Injection on Trastuzumab-Induced Cardiotoxicity via Mitochondrial Protection. Cardiovascular Toxicology. Springer Science and Business Media LLC; 2022; 10.1007/s12012-022-09750-w
• Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice Cite
  Eekhoudt CR, Bortoluzzi T, Varghese SS, Cheung DYC, Christie S, Eastman S, et al. Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice. Current Oncology. MDPI AG; 2022; 29:2941-2953 10.3390/curroncol29050241
• Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study Cite
  Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, et al. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 10.1200/jco.21.01736
• Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer Cite
  Song PN, Mansur A, Lu Y, Della Manna D, Burns A, Samuel S, et al. Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer. Cancers. MDPI AG; 2022; 14:1015 10.3390/cancers14041015
• Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017 Cite
  Vo JB, Ramin C, Barac A, Berrington de Gonzalez A, Veiga L. Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06515-5
• The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study Cite
  Patel R, Lyne-Ethier J, Brogly S, Griffiths R, Hendry JM. The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1254626/v1
• Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors Cite
  Varghese SS, Johnston WJ, Eekhoudt CR, Keats MR, Jassal DS, Grandy SA. Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors. Current Oncology. MDPI AG; 2021; 28:4139-4156 10.3390/curroncol28050351
• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials Cite
  Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Peto R, et al. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet Oncology. Elsevier BV; 2021; 22:1139-1150 10.1016/s1470-2045(21)00288-6
• Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer Cite
  Nami B, Ghanaeian A, Black C, Wang Z. Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer. Life. MDPI AG; 2021; 11:868 10.3390/life11090868
• Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial Cite
  Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, et al. Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial. Research Square Platform LLC; 2021; 10.21203/rs.3.rs-766187/v1
• Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial Cite
  Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, et al. Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06253-0
• Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway Cite
  Kwon Y, Nam K, Kim S. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway. Biochemical Pharmacology. Elsevier BV; 2021;:114635 10.1016/j.bcp.2021.114635
• Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer Cite
  Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, et al. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06192-w
• Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach Cite
  DuMond B, Patel V, Gross A, Fung A, Weber S. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach. Journal of Oncology Pharmacy Practice. SAGE Publications; 2021;:107815522199971 10.1177/1078155221999712
• Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study Cite
  Abdel‐Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo‐Argüelles O, Amir E, et al. Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study. Journal of the American Heart Association. Ovid Technologies (Wolters Kluwer Health); 2021; 10.1161/jaha.119.018393
• FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf injection for subcutaneous use in Patients with HER2-Positive Breast Cancer Cite
  Gao JJ, Osgood CL, Gong Y, Zhang H, Bloomquist EW, Jiang X, et al. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf injection for subcutaneous use in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020;:clincanres.3474.2020 10.1158/1078-0432.ccr-20-3474
• Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018) Cite
  Cottu P, Coudert B, Perol D, Doly A, Manson J, Aujoulat O, et al. Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018). European Journal of Cancer. Elsevier BV; 2020; 141:209-217 10.1016/j.ejca.2020.10.012
• Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer Cite
  Dackus GMHE, Jóźwiak K, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, et al. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05978-8
• Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer Cite
  Abdel-Razeq H, Edaily S, Iweir S, Salam M, Saleh Y, Sughayer M, et al. Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05942-6
• Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study Cite
  Jacobse JN, Schaapveld M, Boekel NB, Hooning MJ, Jager A, Baaijens MHA, et al. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05930-w
• Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients Cite
  Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, et al. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:3743-3752 10.1200/jco.20.00184
• Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
  Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, et al. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2020; 23:259 10.4048/jbc.2020.23.e34
• The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice Cite
  Asselin CY, Lam A, Cheung DYC, Eekhoudt CR, Zhu A, Mittal I, et al. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice. The Journal of Nutrition. Oxford University Press (OUP); 2020; 150:2353-2363 10.1093/jn/nxaa144
• A Polyphenol-Rich Muscadine Grape Extract Inhibits HER + Breast Cancer and Protects Against Trastuzumab-Induced Cardiotoxicity Cite
  Mackert J, Gallagher P, Tallant E. A Polyphenol-Rich Muscadine Grape Extract Inhibits HER + Breast Cancer and Protects Against Trastuzumab-Induced Cardiotoxicity. Current Developments in Nutrition. Oxford University Press (OUP); 2020; 4:334-334 10.1093/cdn/nzaa044_033
• Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients Cite
  Cho H, Lee S, Sim SH, Park IH, Lee KS, Kwak MH, et al. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 182:333-343 10.1007/s10549-020-05703-5
• Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada Cite
  Rushton M, Lima I, Tuna M, Johnson C, Ivars J, Pritchard K, et al. Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2020; 112:1222-1230 10.1093/jnci/djaa054
• Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session Cite
  Deken MM, Kijanka MM, Beltrán Hernández I, Slooter MD, de Bruijn HS, van Diest PJ, et al. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Journal of Controlled Release. Elsevier BV; 2020; 323:269-281 10.1016/j.jconrel.2020.04.030
• Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study Cite
  Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, et al. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 122:1747-1753 10.1038/s41416-020-0815-9
• Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study Cite
  Kaboré EG, Guenancia C, Vaz-Luis I, Di Meglio A, Pistilli B, Coutant C, et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLOS Medicine. Public Library of Science (PLoS); 2019; 16:e1002989 10.1371/journal.pmed.1002989
• Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016) Cite
  Tang M, Schaffer A, Kiely BE, Daniels B, Simes RJ, Lee CK, et al. Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016). British Journal of Cancer. Springer Science and Business Media LLC; 2019; 121:904-911 10.1038/s41416-019-0612-5
• Prevalence and associated factors of weight gain after early breast cancer diagnosis Cite
  Tessomboon K, Chompoonuch S. Prevalence and associated factors of weight gain after early breast cancer diagnosis. Annals of Oncology. Elsevier BV; 2019; 30:vi137 10.1093/annonc/mdz343.090
• Abstract 296: Trastuzumab sensitizes HER2+ breast cancer to increase efficacy of chemotherapyin vitroandin vivo Cite
  Shah A, Jarrett A, Syed A, Yankeelov T, Sorace A. Abstract 296: Trastuzumab sensitizes HER2+ breast cancer to increase efficacy of chemotherapyin vitroandin vivo. Experimental and Molecular Therapeutics. American Association for Cancer Research; 2019; 10.1158/1538-7445.am2019-296
• Abstract 1860: Muscadine grape extract prevents proliferation of trastuzumab-sensitive and -resistant HER2 positive breast cancer cells and has synergistic effects when combined with trastuzumab Cite
  Mackert J, Gallagher PE, Tallant EA. Abstract 1860: Muscadine grape extract prevents proliferation of trastuzumab-sensitive and -resistant HER2 positive breast cancer cells and has synergistic effects when combined with trastuzumab. Cancer Chemistry. American Association for Cancer Research; 2019; 10.1158/1538-7445.am2019-1860
• Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer Cite
  Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. Journal of the American College of Cardiology. Elsevier BV; 2019; 73:2859-2868 10.1016/j.jacc.2019.03.495
• Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Cite
  von Minckwitz G, Huang C, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2019; 380:617-628 10.1056/nejmoa1814017
• Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy Cite
  Wang X, He Y, Fan Z, Wang T, Xie Y, Li J, et al. Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy. Breast Care. S. Karger AG; 2019; 14:388-393 10.1159/000495186
• Abstract P1-11-21: Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial) Cite
  Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, et al. Abstract P1-11-21: Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). Poster Session Abstracts. American Association for Cancer Research; 2019; 10.1158/1538-7445.sabcs18-p1-11-21
• Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy Cite
  Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E, et al. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Canadian Journal of Cardiology. Elsevier BV; 2018; 35:153-159 10.1016/j.cjca.2018.11.028
• A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study Cite
  Lidbrink E, Chmielowska E, Otremba B, Bouhlel A, Lauer S, Liste Hermoso M, et al. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:187-196 10.1007/s10549-018-5058-6
• Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy Cite
  Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, et al. Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy. The Oncologist. Wiley; 2018; 24:313-318 10.1634/theoncologist.2018-0213
• Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project Cite
  Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, et al. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project. British Journal of Cancer. Springer Science and Business Media LLC; 2018; 119:374-380 10.1038/s41416-018-0114-x
• Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients Cite
  Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC: Cardiovascular Imaging. Elsevier BV; 2018; 11:1084-1093 10.1016/j.jcmg.2018.06.005
• Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database Cite
  Choi JY, Cho EY, Choi YJ, Lee JH, Jung SP, Cho KR, et al. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:181-188 10.1007/s10549-018-4809-8
• Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2 Cite
  Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE, Swain SM, et al. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:3942-3948 10.1200/jco.2017.74.1165
• Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients Cite
  Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients. Clinical Breast Cancer. Elsevier BV; 2017; 18:e687-e694 10.1016/j.clbc.2017.11.012
• Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients Cite
  Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients. Clinical Breast Cancer. Elsevier BV; 2018; 18:e687-e694 10.1016/j.clbc.2017.11.012
• Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials Cite
  Yerushalmi R, Dong B, Chapman J, Goss P, Pollak M, Burnell M, et al. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Annals of Oncology. Elsevier BV; 2017; 28:1560-1568 10.1093/annonc/mdx152
• Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany Cite
  Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, et al. Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany. The Oncologist. Wiley; 2017; 22:131-138 10.1634/theoncologist.2016-0193
• Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective Cite
  Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0172731 10.1371/journal.pone.0172731
• Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab Cite
  Blanchette P, Desautels D, Pond G, Bartlett J, Nofech-Mozes S, Yaffe M, et al. Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p6-09-30
• Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials Cite
  Hao S, Tian W, Gao B, Jiang Y, Zhang X, Zhang S, et al. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials. Oncotarget. Impact Journals, LLC; 2017; 8:19923-19933 10.18632/oncotarget.15252
• 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Cite
  Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. Elsevier BV; 2017; 389:1195-1205 10.1016/s0140-6736(16)32616-2
• Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity Cite
  Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 35:870-877 10.1200/jco.2016.68.7830
• Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer Cite
  Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer. JAMA. American Medical Association (AMA); 2017; 317:37 10.1001/jama.2016.18305
• Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer Cite
  Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:487-493 10.1016/j.clbc.2016.07.013
• Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis Cite
  Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:3157-3165 10.1200/jco.2016.67.4846
• The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer Cite
  van Ramshorst MS, van der Heiden-van der Loo M, Dackus GMHE, Linn SC, Sonke GS. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 158:361-371 10.1007/s10549-016-3878-9
• Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer Cite
  Parkinson B, Viney R, Haas M, Goodall S, Srasuebkul P, Pearson S. Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer. PharmacoEconomics. Springer Science and Business Media LLC; 2016; 34:1039-1050 10.1007/s40273-016-0411-2
• Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer Cite
  Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, et al. Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:145-156 10.1007/s10549-016-3790-3
• Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab Cite
  Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, et al. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology. American Medical Association (AMA); 2016; 2:1040 10.1001/jamaoncol.2016.0339
• Breast Cancer Therapy–Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study Cite
  Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, et al. Breast Cancer Therapy–Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2239-2246 10.1200/jco.2015.65.1505
• Clinical predictors of long-term survival in HER2-positive metastatic breast cancer Cite
  Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, et al. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:589-595 10.1007/s10549-016-3705-3
• Cardiomyopathy Associated With Targeted Therapy for Breast Cancer Cite
  Sivagnanam K, Rahman ZU, Paul T. Cardiomyopathy Associated With Targeted Therapy for Breast Cancer. The American Journal of the Medical Sciences. Elsevier BV; 2016; 351:194-199 10.1016/j.amjms.2015.11.014
• A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer Cite
  Kashiwaba M, Ito Y, Takao S, Doihara H, Rai Y, Kanatani K, et al. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2016; 46:407-414 10.1093/jjco/hyw013
• Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab Cite
  Cañas A, López-Sánchez LM, Peñarando J, Valverde A, Conde F, Hernández V, et al. Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. Elsevier BV; 2016; 1862:601-610 10.1016/j.bbadis.2016.02.005
• Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database Cite
  Tseng YD, Uno H, Hughes ME, Niland JC, Wong Y, Theriault R, et al. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2015; 93:622-630 10.1016/j.ijrobp.2015.07.006
• Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab Cite
  Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, et al. Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab. The Breast. Elsevier BV; 2016; 25:22-26 10.1016/j.breast.2015.11.006
• Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer Cite
  Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, et al. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2016; 2:29 10.1001/jamaoncol.2015.3709
• Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474) Cite
  Mason JK, Fu M, Chen J, Thompson LU. Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474). The Journal of Nutritional Biochemistry. Elsevier BV; 2015; 26:16-23 10.1016/j.jnutbio.2014.08.001
• Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells Cite
  Ravacci GR, Brentani MM, Tortelli TC, Torrinhas RSMM, Santos JR, Logullo AF, et al. Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells. BioMed Research International. Hindawi Limited; 2015; 2015:1-13 10.1155/2015/838652
• The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study Cite
  Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, et al. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 108:djv301 10.1093/jnci/djv301
• Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab Cite
  Cao L, Cai G, Chang C, Yang Z, Feng Y, Yu X, et al. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab. Oncotarget. Impact Journals, LLC; 2015; 7:1042-1054 10.18632/oncotarget.6053
• Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab Cite
  Sharieh EA, Awidi AS, Ahram M, Zihlif MA. Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab. Gene. Elsevier BV; 2016; 575:415-420 10.1016/j.gene.2015.09.019
• The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer Cite
  Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, et al. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0136731 10.1371/journal.pone.0136731
• Abstract 913: Natural product sulforaphane selectively inhibits breast cancer stem cells in basal and trastuzumab resistant Her2+ breast cancer. Cite
  Burnett J, Korkaya H, Newman B, Conley S, Connarn J, Sun L, et al. Abstract 913: Natural product sulforaphane selectively inhibits breast cancer stem cells in basal and trastuzumab resistant Her2+ breast cancer.. Experimental and Molecular Therapeutics. American Association for Cancer Research; 2013; 10.1158/1538-7445.am2013-913
• Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment? Cite
  Tognela A, Beith J, Kiely B, Bastick P, Lynch J, Descallar J, et al. Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?. Clinical Breast Cancer. Elsevier BV; 2015; 15:277-284 10.1016/j.clbc.2014.12.012
• Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo Cite
  LIU W, XU J, LIU Y, YU X, TANG X, WANG Z, et al. Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo. Molecular Medicine Reports. Spandidos Publications; 2014; 10:1921-1926 10.3892/mmr.2014.2414
• Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice Cite
  Bonifazi M, Franchi M, Rossi M, Zambelli A, Moja L, Zambon A, et al. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice. The Breast. Elsevier BV; 2014; 23:573-578 10.1016/j.breast.2014.05.022
• Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Cite
  Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet Oncology. Elsevier BV; 2014; 15:640-647 10.1016/s1470-2045(14)70080-4
• Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Cite
  André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. Elsevier BV; 2014; 15:580-591 10.1016/s1470-2045(14)70138-x
• Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab Cite
  Olson E, Abdel-Rasoul M, Maly J, Wu C, Lin N, Shapiro C. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Annals of Oncology. Elsevier BV; 2013; 24:1526-1533 10.1093/annonc/mdt036
• Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab Cite
  Olson E, Abdel-Rasoul M, Maly J, Wu C, Lin N, Shapiro C. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Annals of Oncology. Elsevier BV; 2013; 24:1526-1533 10.1093/annonc/mdt036
• Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer Cite
  Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer. Journal of the American College of Cardiology. Elsevier BV; 2012; 60:2504-2512 10.1016/j.jacc.2012.07.068
• Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab Cite
  Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab. Breast Cancer. Springer Science and Business Media LLC; 2012; 21:563-570 10.1007/s12282-012-0424-4
• Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials Cite
  Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials. Cancer Treatment Reviews. Elsevier BV; 2013; 39:44-50 10.1016/j.ctrv.2012.03.009
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Cite
  Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Elsevier BV; 2012; 379:633-640 10.1016/s0140-6736(11)61847-3
• Adjuvant Trastuzumab in HER2-Positive Breast Cancer Cite
  Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2011; 365:1273-1283 10.1056/nejmoa0910383
• Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions Cite
  Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle. Informa UK Limited; 2011; 10:2959-2966 10.4161/cc.10.17.16359